Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution
Though the actual incidence of an adrenal oligometastasis is between 1.5 and 3.5 %, secondary adrenal neoplasms occur in less than 10 % patients with non-small cell lung cancer (NSCLC). According to 7° ed. TNM staging system, the presence of an adrenal metastasis (M1b disease) configures stage IV, w...
Gespeichert in:
| Veröffentlicht in: | Updates in Surgery 2015-12, Vol.67 (4), p.383-387 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 387 |
|---|---|
| container_issue | 4 |
| container_start_page | 383 |
| container_title | Updates in Surgery |
| container_volume | 67 |
| creator | Barone, Mirko Di Nuzzo, Decio Cipollone, Giuseppe Camplese, Pierpaolo Mucilli, Felice |
| description | Though the actual incidence of an adrenal oligometastasis is between 1.5 and 3.5 %, secondary adrenal neoplasms occur in less than 10 % patients with non-small cell lung cancer (NSCLC). According to 7° ed. TNM staging system, the presence of an adrenal metastasis (M1b disease) configures stage IV, which is usually associated with poor prognosis. We evaluated if metastasectomy in selected patients with oligometastatic disease improves overall survival. A 15-year retrospective study concerning patients with NSCLC was performed and an oligometastatic disease was found in 1.61 % of the patients. 18 adrenalectomies were performed. Clustering the population according to different therapeutic strategies, a benefit in terms of survival was found in patients who underwent adrenalectomy. A statistical relevance was found, indeed, between adrenalectomy (
p
|
| doi_str_mv | 10.1007/s13304-015-0336-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1750441826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A710635582</galeid><sourcerecordid>A710635582</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-33a9e218698ae8893f91aaaffb5f6b3112f13d0af61fb7a7c3902c70ba7923413</originalsourceid><addsrcrecordid>eNp9kU1v3CAQhlHVqImS_IBeKo7pwVsG_NlbtEqbSKvmkFTqDY1ZsFjZsAUsbf59sbztsSANI3jf0QwPIR-BbYCx5ksEIVhZMKgKJkRdnN6RK85EWwgB_P05BwG_LsltjAeWl-iW-IFc8rpqu5rxK3J4Hu3gJ50wJkxWUeddESccR6p0DuPsBqrQKR3o3Y-X7W77-SvFfdAOR3q2RR039OF01MHqLKTWUaTRumFc8phsmpP17oZcGByjvj2f1-Tnt4fX7WOxe_7-tL3fFaoESLl97DSHtu5a1G3bCdMBIhrTV6buBQA3IPYMTQ2mb7BReSquGtZj03FRgrgmd2vdY_C_Zx2TnGxchkGn_RwlNBUrS2h5naWbVTrgqKV1xqeAKu-9nqzyThub7-8bYLWoqpZnA6wGFXyMQRt5DHbC8CaByQWLXLHIjEUuWOQpez6d-5n7Se__Of5CyAK-CmJ-coMO8uDnkD84_qfqHzlFl9Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1750441826</pqid></control><display><type>article</type><title>Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution</title><source>MEDLINE</source><source>SpringerLink_现刊</source><creator>Barone, Mirko ; Di Nuzzo, Decio ; Cipollone, Giuseppe ; Camplese, Pierpaolo ; Mucilli, Felice</creator><creatorcontrib>Barone, Mirko ; Di Nuzzo, Decio ; Cipollone, Giuseppe ; Camplese, Pierpaolo ; Mucilli, Felice</creatorcontrib><description>Though the actual incidence of an adrenal oligometastasis is between 1.5 and 3.5 %, secondary adrenal neoplasms occur in less than 10 % patients with non-small cell lung cancer (NSCLC). According to 7° ed. TNM staging system, the presence of an adrenal metastasis (M1b disease) configures stage IV, which is usually associated with poor prognosis. We evaluated if metastasectomy in selected patients with oligometastatic disease improves overall survival. A 15-year retrospective study concerning patients with NSCLC was performed and an oligometastatic disease was found in 1.61 % of the patients. 18 adrenalectomies were performed. Clustering the population according to different therapeutic strategies, a benefit in terms of survival was found in patients who underwent adrenalectomy. A statistical relevance was found, indeed, between adrenalectomy (
p
< 0.01), metachronous disease (
p
< 0.01), the presence of a homolateral disease (
p
< 0.05) and overall survival. Adrenalectomy should be offered in selected patients with oligometastatic disease.</description><identifier>ISSN: 2038-131X</identifier><identifier>EISSN: 2038-3312</identifier><identifier>DOI: 10.1007/s13304-015-0336-x</identifier><identifier>PMID: 26589602</identifier><language>eng</language><publisher>Milan: Springer Milan</publisher><subject>Adrenal Gland Neoplasms - mortality ; Adrenal Gland Neoplasms - secondary ; Adrenal Gland Neoplasms - surgery ; Adrenalectomy ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - secondary ; Carcinoma, Non-Small-Cell Lung - surgery ; Female ; Humans ; Italy - epidemiology ; Lung cancer, Non-small cell ; Lung cancer, Small cell ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Metastasis ; Middle Aged ; Prognosis ; Retrospective Studies ; Review Article ; Surgery ; Survival Rate</subject><ispartof>Updates in Surgery, 2015-12, Vol.67 (4), p.383-387</ispartof><rights>Italian Society of Surgery (SIC) 2015</rights><rights>COPYRIGHT 2015 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-33a9e218698ae8893f91aaaffb5f6b3112f13d0af61fb7a7c3902c70ba7923413</citedby><cites>FETCH-LOGICAL-c411t-33a9e218698ae8893f91aaaffb5f6b3112f13d0af61fb7a7c3902c70ba7923413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13304-015-0336-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13304-015-0336-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26589602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barone, Mirko</creatorcontrib><creatorcontrib>Di Nuzzo, Decio</creatorcontrib><creatorcontrib>Cipollone, Giuseppe</creatorcontrib><creatorcontrib>Camplese, Pierpaolo</creatorcontrib><creatorcontrib>Mucilli, Felice</creatorcontrib><title>Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution</title><title>Updates in Surgery</title><addtitle>Updates Surg</addtitle><addtitle>Updates Surg</addtitle><description>Though the actual incidence of an adrenal oligometastasis is between 1.5 and 3.5 %, secondary adrenal neoplasms occur in less than 10 % patients with non-small cell lung cancer (NSCLC). According to 7° ed. TNM staging system, the presence of an adrenal metastasis (M1b disease) configures stage IV, which is usually associated with poor prognosis. We evaluated if metastasectomy in selected patients with oligometastatic disease improves overall survival. A 15-year retrospective study concerning patients with NSCLC was performed and an oligometastatic disease was found in 1.61 % of the patients. 18 adrenalectomies were performed. Clustering the population according to different therapeutic strategies, a benefit in terms of survival was found in patients who underwent adrenalectomy. A statistical relevance was found, indeed, between adrenalectomy (
p
< 0.01), metachronous disease (
p
< 0.01), the presence of a homolateral disease (
p
< 0.05) and overall survival. Adrenalectomy should be offered in selected patients with oligometastatic disease.</description><subject>Adrenal Gland Neoplasms - mortality</subject><subject>Adrenal Gland Neoplasms - secondary</subject><subject>Adrenal Gland Neoplasms - surgery</subject><subject>Adrenalectomy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Female</subject><subject>Humans</subject><subject>Italy - epidemiology</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung cancer, Small cell</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Review Article</subject><subject>Surgery</subject><subject>Survival Rate</subject><issn>2038-131X</issn><issn>2038-3312</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v3CAQhlHVqImS_IBeKo7pwVsG_NlbtEqbSKvmkFTqDY1ZsFjZsAUsbf59sbztsSANI3jf0QwPIR-BbYCx5ksEIVhZMKgKJkRdnN6RK85EWwgB_P05BwG_LsltjAeWl-iW-IFc8rpqu5rxK3J4Hu3gJ50wJkxWUeddESccR6p0DuPsBqrQKR3o3Y-X7W77-SvFfdAOR3q2RR039OF01MHqLKTWUaTRumFc8phsmpP17oZcGByjvj2f1-Tnt4fX7WOxe_7-tL3fFaoESLl97DSHtu5a1G3bCdMBIhrTV6buBQA3IPYMTQ2mb7BReSquGtZj03FRgrgmd2vdY_C_Zx2TnGxchkGn_RwlNBUrS2h5naWbVTrgqKV1xqeAKu-9nqzyThub7-8bYLWoqpZnA6wGFXyMQRt5DHbC8CaByQWLXLHIjEUuWOQpez6d-5n7Se__Of5CyAK-CmJ-coMO8uDnkD84_qfqHzlFl9Y</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Barone, Mirko</creator><creator>Di Nuzzo, Decio</creator><creator>Cipollone, Giuseppe</creator><creator>Camplese, Pierpaolo</creator><creator>Mucilli, Felice</creator><general>Springer Milan</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope></search><sort><creationdate>20151201</creationdate><title>Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution</title><author>Barone, Mirko ; Di Nuzzo, Decio ; Cipollone, Giuseppe ; Camplese, Pierpaolo ; Mucilli, Felice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-33a9e218698ae8893f91aaaffb5f6b3112f13d0af61fb7a7c3902c70ba7923413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adrenal Gland Neoplasms - mortality</topic><topic>Adrenal Gland Neoplasms - secondary</topic><topic>Adrenal Gland Neoplasms - surgery</topic><topic>Adrenalectomy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Female</topic><topic>Humans</topic><topic>Italy - epidemiology</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung cancer, Small cell</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Review Article</topic><topic>Surgery</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barone, Mirko</creatorcontrib><creatorcontrib>Di Nuzzo, Decio</creatorcontrib><creatorcontrib>Cipollone, Giuseppe</creatorcontrib><creatorcontrib>Camplese, Pierpaolo</creatorcontrib><creatorcontrib>Mucilli, Felice</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Academic OneFile</collection><collection>MEDLINE - Academic</collection><jtitle>Updates in Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barone, Mirko</au><au>Di Nuzzo, Decio</au><au>Cipollone, Giuseppe</au><au>Camplese, Pierpaolo</au><au>Mucilli, Felice</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution</atitle><jtitle>Updates in Surgery</jtitle><stitle>Updates Surg</stitle><addtitle>Updates Surg</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>67</volume><issue>4</issue><spage>383</spage><epage>387</epage><pages>383-387</pages><issn>2038-131X</issn><eissn>2038-3312</eissn><abstract>Though the actual incidence of an adrenal oligometastasis is between 1.5 and 3.5 %, secondary adrenal neoplasms occur in less than 10 % patients with non-small cell lung cancer (NSCLC). According to 7° ed. TNM staging system, the presence of an adrenal metastasis (M1b disease) configures stage IV, which is usually associated with poor prognosis. We evaluated if metastasectomy in selected patients with oligometastatic disease improves overall survival. A 15-year retrospective study concerning patients with NSCLC was performed and an oligometastatic disease was found in 1.61 % of the patients. 18 adrenalectomies were performed. Clustering the population according to different therapeutic strategies, a benefit in terms of survival was found in patients who underwent adrenalectomy. A statistical relevance was found, indeed, between adrenalectomy (
p
< 0.01), metachronous disease (
p
< 0.01), the presence of a homolateral disease (
p
< 0.05) and overall survival. Adrenalectomy should be offered in selected patients with oligometastatic disease.</abstract><cop>Milan</cop><pub>Springer Milan</pub><pmid>26589602</pmid><doi>10.1007/s13304-015-0336-x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2038-131X |
| ispartof | Updates in Surgery, 2015-12, Vol.67 (4), p.383-387 |
| issn | 2038-131X 2038-3312 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1750441826 |
| source | MEDLINE; SpringerLink_现刊 |
| subjects | Adrenal Gland Neoplasms - mortality Adrenal Gland Neoplasms - secondary Adrenal Gland Neoplasms - surgery Adrenalectomy Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - secondary Carcinoma, Non-Small-Cell Lung - surgery Female Humans Italy - epidemiology Lung cancer, Non-small cell Lung cancer, Small cell Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medical research Medicine Medicine & Public Health Medicine, Experimental Metastasis Middle Aged Prognosis Retrospective Studies Review Article Surgery Survival Rate |
| title | Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A27%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oligometastatic%20non-small%20cell%20lung%20cancer%20(NSCLC):%20adrenal%20metastases.%20Experience%20in%20a%20single%20institution&rft.jtitle=Updates%20in%20Surgery&rft.au=Barone,%20Mirko&rft.date=2015-12-01&rft.volume=67&rft.issue=4&rft.spage=383&rft.epage=387&rft.pages=383-387&rft.issn=2038-131X&rft.eissn=2038-3312&rft_id=info:doi/10.1007/s13304-015-0336-x&rft_dat=%3Cgale_proqu%3EA710635582%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1750441826&rft_id=info:pmid/26589602&rft_galeid=A710635582&rfr_iscdi=true |